ESMO Asia 2018 Congress [ESMO Media Alert]

  • Date: 06 Nov 2018

LUGANO- SINGAPORE – The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the fourth ESMO Asia 2018 Congress. Held 23–25 November 2018 at the Suntec Convention and Exhibition Centre in Singapore, the scientific and educational congress will keep oncology professionals in the Asia-Pacific region up to date with the fast pace of oncology science and education, and provide important networking opportunities with international peers.

Clear trends in providing ultimate cancer care emerge from the ESMO Asia 2018 Programme where international studies will be presented with an eye on providing useful perspectives for local practitioners. Among the 578 accepted abstracts, you may find of particular interest:

  • Primary erfficacy and safety  results of adding atezolizumab to standard treatment of patients with extensive stage NSCLC: the Impower133 trial
  • Primary results of  a phase III, randomised open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC: the ALESIA Trial
  • Results of maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation: the SOLO1 trial

The congress programme features numerous sessions in which global leaders will present the latest knowledge on state-of-the-art treatment of cancer, such as:

If your focus is not only clinical, you can follow thought-provoking debates:

The ESMO Asia 2018 Congress is expected to draw around 3,000 participants and is supported by 21 oncology associations in the region, including the Singapore Society of Oncology and oncology societies from Australia, Bangladesh, China, Hong Kong, India, Indonesia, Iran, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, South Korea, Taiwan, Thailand and Uzbekistan.

Media registration

ESMO welcomes members of the press interested in reporting on cancer. Registration to the ESMO Asia 2018 Congress is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO Media Policy.
To register as press, please fill out the media registration.

Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO Asia 2018 Congress

Official Congress Hashtag:  #ESMOAsia18

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With more than 20,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.